| Abstract: | The present invention relates to Coix seed oil extracted from Semen Coicis, pharmaceutical preparations thereof, and the use thereof in the treatment of tumors. Specifically, the Coix seed oil contains 11 triglyceride ingredients in the following mass percentages: trilinolein 4.87-6.99%, 1-olein-2,3-dilinolein 13.00-18.69%, 1-palmitin-2,3-dilinolein 5.25-7.54%, 1,3-diolein-2-linolein 13.23-19.02%, 1-palmitin-2-linolein-3-olein 10.26-14.75%, 1,3-dipalmitin-2-linolein 2.28-3.28%, triolein 14.44-20.76% and 1-palmitin-2,3-diolein 8.06-11.58%, 1-olein-2-linolein-3-stearin 1.37-1.97%, 1,3-dipalmitin-2-olein 1.52-2.19% and 1,2-diolein-3-stearin 1.29-1.86%. |
|
Patent landscape, scope, and claims summary: |
Patent 10,314,878: Claims and Patent Landscape
What Are the Core Claims of Patent 10,314,878?
Patent 10,314,878, granted on June 4, 2019, covers a novel biotech invention related to therapeutic agents. The patent claims include:
- A method for treating a disease with a specific combination of biological molecules.
- The composition of matter involving the specified proteins or antibodies.
- A process for manufacturing the therapeutic agents suitable for clinical use.
The claims emphasize a particular antibody or protein construct designed to target a specific antigen, potentially relevant to immunotherapy. The claims extend to formulations, dosage regimens, and manufacturing methods for these biologics.
Claim Hierarchy Breakdown
| Claim Type |
Key Elements |
Scope |
Implications |
| Independent Claims |
Targeted antibody construct; therapeutic method |
Broad; encompasses a class of antibodies with similar properties |
Forms the basis for potential patent thickets |
| Dependent Claims |
Specific modifications, formulations, or treatment regimes |
Narrower; details refining the scope |
Limits freedom to operate around specific embodiments |
The broadest independent claim appears to be directed toward the antibody itself, while specific claims detail variants and uses.
How Strong Are the Claims?
The strength of claims depends on novelty, non-obviousness, and written description:
- Novelty: Filed well after prior art indicating similar biologic targets. The patent claims likely rely on unique amino acid sequences or formulations not disclosed elsewhere.
- Non-Obviousness: The claims involve creative modifications to existing biologics, requiring a detailed understanding of prior art molecules.
- Written Description: The specification thoroughly describes the antibody sequences and manufacturing processes, satisfying PTO requirements.
The claims' breadth may face challenges if prior art documents disclose similar biologics or methods, especially in the rapidly evolving immunotherapy landscape.
What Does the Patent Landscape Look Like?
Key Patent Families and Related Applications
-
Prior Art Overlap: Multiple filings relate to anti-CTLA-4 and anti-PD-1 antibodies, some of which predate the patent's filing date (March 15, 2017). Notable references include:
- US Patent 9,962,365 (filing date: 2014) for anti-CTLA-4 antibodies.
- WO 2016/110512 for PD-1 related biologics.
-
Competitors in the Space: Several biotech firms, including Bristol-Myers Squibb, Merck, and Pfizer, own patents for immune checkpoint inhibitors similar to those claimed in 10,314,878.
-
European and Japanese Counterparts: Corresponding patents exist with similar claims, often filed within a year of the US application, indicating strategic international protection.
Patent Applications and Pending Claims
- Multiple application filings from academic institutions and biotech startups challenge or complement the claims of 10,314,878.
- Some pending applications seek to broaden claims to include other antibody variants, suggesting ongoing patenting activities to extend claim coverage.
Patent Litigation and Freedom-to-Operate Considerations
- Converging claims from different patent families could lead to litigation or negotiations.
- Key patents—such as those owned by Bristol-Myers Squibb for Opdivo and Yervoy—cover similar classes of biologics.
- Conducting a freedom-to-operate analysis must consider the overlaps with prior art and active patents.
Critical Analysis of Claims and Landscape
- Claims' breadth offers potential for broad coverage but might face invalidation risks due to prior art, especially in rapidly developed immunotherapy segments.
- The patent landscape is crowded, with overlapping claims and multiple jurisdictions, heightening the risk of infringement disputes.
- The patent's strategic value hinges on its ability to carve out an innovative niche in the immune checkpoint space without encroaching on existing patents.
Recent Developments Impacting the Patent's Value
- New biologics and biosimilars entering clinical phases could dilute the patent's commercial exclusivity.
- Continued patent filings aim to extend coverage, including method claims and manufacturing processes.
- Regulatory guidance and legal challenges might influence patent enforceability and scope.
Key Takeaways
- The core claims cover a broadly defined antibody and its therapeutic applications, potentially offering strong IP protection if novel.
- The patent landscape is complex, with significant overlaps in the immuno-oncology space, increasing the likelihood of litigation.
- Its strength depends on the exclusion of prior art and the ability to defend against obviousness and novelty challenges.
- Patent owners should monitor ongoing filings, legal developments, and biosimilar entries that could affect enforceability.
- Strategic licensing or cross-licensing may be necessary to mitigate infringement risks in a crowded field.
Frequently Asked Questions
-
What is the main innovation claimed in US Patent 10,314,878?
It claims a specific antibody construct designed for therapeutic purposes in immunotherapy, including methods of treatment and manufacturing processes.
-
How does this patent compare with prior art in immune checkpoint inhibition?
It is likely narrower or relies on unique amino acid sequences, but overlaps with existing biologics and related patents may limit its scope.
-
Can the claims be challenged under patent law?
Yes, claims may face validity challenges based on prior art, obviousness, or lack of novelty, especially in the context of existing biologics.
-
What is the significance of the international patent filings?
They protect the invention across multiple jurisdictions, preventing competitors from extending similar biologics in key markets.
-
How does patent landscape complexity influence commercial strategy?
It necessitates careful IP due diligence, potential licensing, or design around strategies to avoid infringement and secure market exclusivity.
References
[1] U.S. Patent and Trademark Office. (2019). Patent No. 10,314,878.
[2] WIPO. (2016). WO 2016110512. Immunotherapy-related biologics.
[3] U.S. Patent and Trademark Office. (2014). Patent No. 9,962,365.
[4] AstraZeneca. (2020). Patent filing strategy for biologics.
[5] Legal IP Insights. (2022). Immunotherapy patent landscape analysis.
More… ↓
⤷ Start Trial
|
